Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 566-579

  Yang, Feng ^a   Jin, Chen ^a   Subedi, Sabin ^a   Lee, Chong Lek ^a   Wang, Qiang ^a   Jiang, Yongjian ^a   Li, Ji ^a   Di, Yang ^a   Fu, Deliang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Nanoparticle; Pancreatic cancer; Personalized medicine; Theranostic nanomedicine

Indexed keywords

CARBON NANOTUBE; DENDRIMER; GOLD NANOPARTICLE; LIPOSOME; MULTI WALLED NANOTUBE; NANOCAGE; NANOMATERIAL; NANOPARTICLE; POLYMER; QUANTUM DOT; SILICON DIOXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER THERAPY; EARLY DIAGNOSIS; HUMAN; HYPERTHERMIC THERAPY; MEDICAL RESEARCH; MOLECULAR IMAGING; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PANCREAS CANCER; PHOTODYNAMIC THERAPY; REVIEW;

ANIMALS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; NANOTECHNOLOGY; PANCREATIC NEOPLASMS; RESEARCH;

EID: 84861694755     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.02.003     Document Type: Review

References (184)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Baxter N.N., Whitson B.A., Tuttle T.M. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol 2007, 14:1320-1326.
3. Yang F., Jin C., Jiang Y., Li J., Di Y., Ni Q., et al. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Cancer Treat Rev 2011, 37(8):633-642.
4. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966.
5. Spano J.P., Chodkiewicz C., Maurel J., Wong R., Wasan H., Barone C., et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008, 371:2101-2108.
6. Yang L., Mao H., Cao Z., Wang Y.A., Peng X., Wang X., et al. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology 2009, 136:1514-1525. [e2].
7. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
8. Lee C.J., Dosch J., Simeone D.M. Pancreatic cancer stem cells. J Clin Oncol 2008, 26:2806-2812.
9. Simeone D.M. Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res 2008, 14:5646-5648.
10. Liu Z., Peng R. Inorganic nanomaterials for tumor angiogenesis imaging. Eur J Nucl Med Mol Imaging 2010, 37(Suppl. 1):S147-S163.
11. Yezhelyev M., Yacoub R., O'Regan R. Inorganic nanoparticles for predictive oncology of breast cancer. Nanomedicine (Lond) 2009, 4:83-103.
12. Cao Y.C. Nanomaterials for biomedical applications. Nanomedicine (Lond) 2008, 3:467-469.
13. Pridgen E.M., Langer R., Farokhzad O.C. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (Lond) 2007, 2:669-680.
14. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003, 2:347-360.
15. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
16. Khemtong C., Kessinger C.W., Gao J. Polymeric nanomedicine for cancer MR imaging and drug delivery. Chem Commun (Camb) 2009, 3497-3510.
17. Ljubimova J.Y., Fujita M., Ljubimov A.V., Torchilin V.P., Black K.L., Holler E. Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine (Lond) 2008, 3:247-265.
18. Matsumura Y. Polymeric micellar delivery systems in oncology. Jpn J Clin Oncol 2008, 38:793-802.
19. Boulikas T. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 2009, 18:1197-1218.
20. Yang F., Hu J., Yang D., Long J., Luo G., Jin C., et al. Pilot study of targeting magnetic carbon nanotubes to lymph nodes. Nanomedicine (Lond) 2009, 4:317-330.
21. Zhuo Y., Yuan R., Chai Y.Q., Hong C.L. Functionalized SiO2 labeled CA19-9 antibodies: a new strategy for signal amplification of antigen-antibody sensing processes. Analyst 2010, 135:2036-2042.
22. Mahmood M., Karmakar A., Fejleh A., Mocan T., Iancu C., Mocan L., et al. Synergistic enhancement of cancer therapy using a combination of carbon nanotubes and anti-tumor drug. Nanomedicine (Lond) 2009, 4:883-893.
23. Yang F., Jin C., Yang D., Jiang Y., Li J., Di Y., et al. Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment. Eur J Cancer 2011, 47(12):1873-1882.
24. Arsawang U., Saengsawang O., Rungrotmongkol T., Sornmee P., Wittayanarakul K., Remsungnen T., et al. How do carbon nanotubes serve as carriers for gemcitabine transport in a drug delivery system?. J Mol Graph Model 2011, 29:591-596.
25. Stacey M., Osgood C., Kalluri B.S., Cao W., Elsayed-Ali H., Abdel-Fattah T. Nanosecond pulse electrical fields used in conjunction with multi-wall carbon nanotubes as a potential tumor treatment. Biomed Mater 2011, 6:011002.
26. Welsher K., Sherlock S.P., Dai H. Deep-tissue anatomical imaging of mice using carbon nanotube fluorophores in the second near-infrared window. Proc Natl Acad Sci USA 2011, 108:8943-8948.
27. Mocan L., Tabaran F.A., Mocan T., Bele C., Orza A.I., Lucan C., et al. Selective ex-vivo photothermal ablation of human pancreatic cancer with albumin functionalized multiwalled carbon nanotubes. Int J Nanomed 2011, 6:915-928.
28. Liu Q., Liu A., Gao F., Weng S., Zhong G., Liu J., et al. Coupling technique of random amplified polymorphic DNA and nanoelectrochemical sensor for mapping pancreatic cancer genetic fingerprint. Int J Nanomed 2011, 6:2933-2939.
29. Karmakar A., Iancu C., Bartos D.M., Mahmood M.W., Ghosh A., Xu Y., et al. Raman spectroscopy as a detection and analysis tool for in vitro specific targeting of pancreatic cancer cells by EGF-conjugated, single-walled carbon nanotubes. J Appl Toxicol 2011, 10.1002/jat.1742.
30. Kumar R., Roy I., Ohulchanskyy T.Y., Goswami L.N., Bonoiu A.C., Bergey E.J., et al. Covalently dye-linked, surface-controlled, and bioconjugated organically modified silica nanoparticles as targeted probes for optical imaging. ACS Nano 2008, 2:449-456.
31. Liong M., Lu J., Kovochich M., Xia T., Ruehm S.G., Nel A.E., et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2008, 2:889-896.
32. Xia T., Kovochich M., Liong M., Meng H., Kabehie S., George S., et al. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 2009, 3:3273-3286.
33. Lu J., Choi E., Tamanoi F., Zink J.I. Light-activated nanoimpeller-controlled drug release in cancer cells. Small 2008, 4:421-426.
34. Lu J., Li Z., Zink J.I., Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine 2012, 8(2):212-220.
35. Xue M., Zhong X., Shaposhnik Z., Qu Y., Tamanoi F., Duan X., et al. pH-operated mechanized porous silicon nanoparticles. J Am Chem Soc 2011, 133:8798-8801.
36. Vivero-Escoto J.L., Taylor-Pashow K.M., Huxford R.C., DellaRocca J., Okoruwa C., An H., et al. Multifunctional mesoporous silica nanospheres with cleavable Gd(III) chelates as mri contrast agents: synthesis, characterization, target-specificity, and renal clearance. Small 2011, 7:3519-3528.
37. Yong K.T., Ding H., Roy I., Law W.C., Bergey E.J., Maitra A., et al. Imaging pancreatic cancer using bioconjugated InP quantum dots. ACS Nano 2009, 3:502-510.
38. Yang L., Mao H., Wang Y.A., Cao Z., Peng X., Wang X., et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 2009, 5:235-243.
39. Qian J., Yong K.T., Roy I., Ohulchanskyy T.Y., Bergey E.J., Lee H.H., et al. Imaging pancreatic cancer using surface-functionalized quantum dots. J Phys Chem B 2007, 111:6969-6972.
40. Chang S.Q., Dai Y.D., Kang B., Han W., Mao L., Chen D. UV-enhanced cytotoxicity of thiol-capped CdTe quantum dots in human pancreatic carcinoma cells. Toxicol Lett 2009, 188:104-111.
41. Law W.C., Yong K.T., Roy I., Ding H., Hu R., Zhao W., et al. Aqueous-phase synthesis of highly luminescent CdTe/ZnTe core/shell quantum dots optimized for targeted bioimaging. Small 2009, 5:1302-1310.
42. Yong K.T. Mn-doped near-infrared quantum dots as multimodal targeted probes for pancreatic cancer imaging. Nanotechnology 2009, 20:015102.
43. Erogbogbo F., Yong K.T., Roy I., Xu G., Prasad P.N., Swihart M.T. Biocompatible luminescent silicon quantum dots for imaging of cancer cells. ACS Nano 2008, 2:873-878.
44. Choi H.S., Ipe B.I., Misra P., Lee J.H., Bawendi M.G., Frangioni J.V. Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett 2009, 9:2354-2359.
45. Glazer E.S., Curley S.A. Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles. Cancer 2010, 116:3285-3293.
46. Hu R., Yong K.T., Roy I., Ding H., Law W.C., Cai H., et al. Functionalized near-infrared quantum dots for in vivo tumor vasculature imaging. Nanotechnology 2010, 21:145105.
47. Chang S.Q., Dai Y.D., Kang B., Han W., Chen D. Gamma-radiation synthesis of silk fibroin coated CdSe quantum dots and their biocompatibility and photostability in living cells. J Nanosci Nanotechnol 2009, 9:5693-5700.
48. Gu B., Xu C., Yang C., Liu S., Wang M. ZnO quantum dot labeled immunosensor for carbohydrate antigen 19-9. Biosens Bioelectron 2011, 26:2720-2723.
49. Yong K.T. Biophotonics and biotechnology in pancreatic cancer: cyclic RGD-peptide-conjugated type II quantum dots for in vivo imaging. Pancreatology 2010, 10:553-564.
50. Yong K.T., Roy I., Law W.C., Hu R. Synthesis of cRGD-peptide conjugated near-infrared CdTe/ZnSe core-shell quantum dots for in vivo cancer targeting and imaging. Chem Commun (Camb) 2010, 46:7136-7138.
51. Ding H., Yong K.T., Law W.C., Roy I., Hu R., Wu F., et al. Non-invasive tumor detection in small animals using novel functional Pluronic nanomicelles conjugated with anti-mesothelin antibody. Nanoscale 2011, 3:1813-1822.
52. Zaman M.B., Baral T.N., Jakubek Z.J., Zhang J., Wu X., Lai E., et al. Single-domain antibody bioconjugated near-IR quantum dots for targeted cellular imaging of pancreatic cancer. J Nanosci Nanotechnol 2011, 11:3757-3763.
53. Duan Y.J., Liang H.Y., Jin W.J., Cui Z.J. Substance P conjugated to CdTe quantum dots triggers cytosolic calcium concentration oscillations and induces quantum dots internalization in the pancreatic carcinoma cell line AR4-2J. Anal Bioanal Chem 2011, 400:2995-3003.
54. Yong K.T., Hu R., Roy I., Ding H., Vathy L.A., Bergey E.J., et al. Tumor targeting and imaging in live animals with functionalized semiconductor quantum rods. ACS Appl Mater Interfaces 2009, 1:710-719.
55. Yong K.T., Roy I., Pudavar H.E., Bergey E.J., Tramposch K.M., Swihart M.T., et al. Multiplex imaging of pancreatic cancer cells by using functionalized quantum rods. Adv Mater 2008, 20:1412-1417.
56. Patra C.R., Bhattacharya R., Mukhopadhyay D., Mukherjee P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev 2010, 62:346-361.
57. Gannon C.J., Patra C.R., Bhattacharya R., Mukherjee P., Curley S.A. Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J Nanobiotechnol 2008, 6:2.
58. Eck W., Craig G., Sigdel A., Ritter G., Old L.J., Tang L., et al. PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue. ACS Nano 2008, 2:2263-2272.
59. Patra C.R., Bhattacharya R., Wang E., Katarya A., Lau J.S., Dutta S., et al. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res 2008, 68:1970-1978.
60. Hu R., Yong K.T., Roy I., Ding H., He S., Prasad P.N. Metallic nanostructures as localized plasmon resonance enhanced scattering probes for multiplex dark field targeted imaging of cancer cells. J Phys Chem C Nanomater Interfaces 2009, 113:2676-2684.
61. Du D., Xu X., Wang S., Zhang A. Reagentless amperometric carbohydrate antigen 19-9 immunosensor based on direct electrochemistry of immobilized horseradish peroxidase. Talanta 2007, 71:1257-1262.
62. Yanez-Sedeno P., Pingarron J.M. Gold nanoparticle-based electrochemical biosensors. Anal Bioanal Chem 2005, 382:884-886.
63. Glazer E.S., Massey K.L., Zhu C., Curley S.A. Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles. Surgery 2010, 148:319-324.
64. Glazer E.S., Zhu C., Massey K.L., Thompson C.S., Kaluarachchi W.D., Hamir A.N., et al. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin Cancer Res 2010, 16:5712-5721.
65. Trono J.D., Mizuno K., Yusa N., Matsukawa T., Yokoyama K., Uesaka M. Size, concentration and incubation time dependence of gold nanoparticle uptake into pancreas cancer cells and its future application to X-Ray Drug Delivery System. J Radiat Res (Tokyo) 2011, 52:103-109.
66. Khan J.A., Kudgus R.A., Szabolcs A., Dutta S., Wang E., Cao S., et al. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS One 2011, 6:e20347.
67. Libutti S.K., Paciotti G.F., Byrnes A.A., Alexander H.R., Gannon W.E., Walker M., et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010, 16:6139-6149.
68. Sobhan M.A., Sreenivasan V.K., Withford M.J., Goldys E.M. Non-specific internalization of laser ablated pure gold nanoparticles in pancreatic tumor cell. Colloids Surf B Biointerfaces 2012, 92:190-195.
69. Bhattacharyya S., Singh R.D., Pagano R., Robertson J.D., Bhattacharya R., Mukherjee P. Switching the targeting pathways of a therapeutic antibody by nanodesign. Angew Chem Int Ed Engl 2012, 51(7):1563-1567.
70. Homan K., Shah J., Gomez S., Gensler H., Karpiouk A., Peppas L.B., et al. Combined ultrasound and photoacoustic imaging of pancreatic cancer using nanocage contrast agents. Proc SPIE 2009, 7177:71771M.
71. Medarova Z., Pham W., Kim Y., Dai G., Moore A. In vivo imaging of tumor response to therapy using a dual-modality imaging strategy. Int J Cancer 2006, 118:2796-2802.
72. Kelly K.A., Bardeesy N., Anbazhagan R., Gurumurthy S., Berger J., Alencar H., et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med 2008, 5:e85.
73. Moore A., Medarova Z., Potthast A., Dai G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004, 64:1821-1827.
74. Erten A., Wrasidlo W., Scadeng M., Esener S., Hoffman R.M., Bouvet M., et al. Magnetic resonance and fluorescence imaging of doxorubicin-loaded nanoparticles using a novel in vivo model. Nanomedicine 2010, 6:797-807.
75. Kumagai M., Kano M.R., Morishita Y., Ota M., Imai Y., Nishiyama N., et al. Enhanced magnetic resonance imaging of experimental pancreatic tumor in vivo by block copolymer-coated magnetite nanoparticles with TGF-beta inhibitor. J Control Release 2009, 140:306-311.
76. Montet X., Weissleder R., Josephson L. Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjug Chem 2006, 17:905-911.
77. Yamada K., Oda T., Hashimoto S., Enomoto T., Ohkohchi N., Ikeda H., et al. Minimally required heat doses for various tumour sizes in induction heating cancer therapy determined by computer simulation using experimental data. Int J Hyperthermia 2010, 26:465-474.
78. Wang L., Dong J., Ouyang W., Wang X., Tang J. Anticancer effect and feasibility study of hyperthermia treatment of pancreatic cancer using magnetic nanoparticles. Oncol Rep 2012, 27:719-726.
79. 4 nanoparticles. Int J Nanomed 2011, 6:1929-1935.
80. Barth B.M., Sharma R., Altinoglu E.I., Morgan T.T., Shanmugavelandy S.S., Kaiser J.M., et al. Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano 2010, 4:1279-1287.
81. Ji S.R., Liu C., Zhang B., Yang F., Xu J., Long J., et al. Carbon nanotubes in cancer diagnosis and therapy. Biochim Biophys Acta 2010, 1806:29-35.
82. Liu Z., Tabakman S., Welsher K., Dai H. Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery. Nano Res 2009, 2:85-120.
83. Yang D., Yang F., Hu J., Long J., Wang C., Fu D., et al. Hydrophilic multi-walled carbon nanotubes decorated with magnetite nanoparticles as lymphatic targeted drug delivery vehicles. Chem Commun (Camb) 2009, 4447-4449.
84. Pramanik M., Song K.H., Swierczewska M., Green D., Sitharaman B., Wang L.V. In vivo carbon nanotube-enhanced non-invasive photoacoustic mapping of the sentinel lymph node. Phys Med Biol 2009, 54:3291-3301.
85. Li J.J., Yang F., Guo G.Q., Yang D., Long J., Fu D.L., et al. Preparation of biocompatible multi-walled carbon nanotubes as potential tracers for sentinel lymph nodes. Polym Int 2010, 59:169-174.
86. Kim J.W., Galanzha E.I., Shashkov E.V., Moon H.M., Zharov V.P. Golden carbon nanotubes as multimodal photoacoustic and photothermal high-contrast molecular agents. Nat Nanotechnol 2009, 4:688-694.
87. Boczkowski J., Lanone S. Potential uses of carbon nanotubes in the medical field: how worried should patients be?. Nanomedicine (Lond) 2007, 2:407-410.
88. Simeonova P.P. Update on carbon nanotube toxicity. Nanomedicine (Lond) 2009, 4:373-375.
89. Sekhon B.S., Kamboj S.R. Inorganic nanomedicine - part 2. Nanomedicine 2010, 6:612-618.
90. Mansur H.S. Quantum dots and nanocomposites. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 2:113-129.
91. Zrazhevskiy P., Gao X. Multifunctional quantum dots for personalized medicine. Nano Today 2009, 4:414-428.
92. Kosaka N., McCann T.E., Mitsunaga M., Choyke P.L., Kobayashi H. Real-time optical imaging using quantum dot and related nanocrystals. Nanomedicine (Lond) 2010, 5:765-776.
93. Kim S., Lim Y.T., Soltesz E.G., De Grand A.M., Lee J., Nakayama A., et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004, 22:93-97.
94. Muthu M.S., Singh S. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine (Lond) 2009, 4:105-118.
95. Sekhon B.S., Kamboj S.R. Inorganic nanomedicine - part 1. Nanomedicine 2010, 6:516-522.
96. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
97. Yezhelyev M.V., Gao X., Xing Y., Al-Hajj A., Nie S., O'Regan R.M. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 2006, 7:657-667.
98. Guimaraes A.R., Rakhlin E., Weissleder R., Thayer S.P. Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft model. Pancreas 2008, 37:440-444.
99. Wang X., Yang L., Chen Z.G., Shin D.M. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 2008, 58:97-110.
100. Lin M.M., Kim H.H., Kim H., Dobson J., Kim do K. Surface activation and targeting strategies of superparamagnetic iron oxide nanoparticles in cancer-oriented diagnosis and therapy. Nanomedicine (Lond) 2010, 5:109-133.
101. Scheinberg D.A., Villa C.H., Escorcia F.E., McDevitt M.R. Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nat Rev Clin Oncol 2010, 7:266-276.
102. Xiong H.Q. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 2004, 54(Suppl 1):S69-S77.
103. Koorstra J.B., Hustinx S.R., Offerhaus G.J., Maitra A. Pancreatic carcinogenesis. Pancreatology 2008, 8:110-125.
104. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
105. Korc M. Pancreatic cancer-associated stroma production. Am J Surg 2007, 194:S84-S86.
106. Bausch D., Thomas S., Mino-Kenudson M., Fernandez-del C.C., Bauer T.W., Williams M., et al. Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res 2011, 17:302-309.
107. Luo G., Yu X., Jin C., Yang F., Fu D., Long J., et al. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm 2010, 385:150-156.
108. Wang W., Lin J., Guha S., Tong Z., Cameron A.G., Zhang F., et al. Target-specific agents imaging ectopic and orthotopic human pancreatic cancer xenografts. Pancreas 2011, 40:689-694.
109. Nagaraj V.J., Aithal S., Eaton S., Bothara M., Wiktor P., Prasad S. NanoMonitor: a miniature electronic biosensor for glycan biomarker detection. Nanomedicine (Lond) 2010, 5:369-378.
110. Ding Y., Liu J., Jin X., Lu H., Shen G., Yu R. Poly-l-lysine/hydroxyapatite/carbon nanotube hybrid nanocomposite applied for piezoelectric immunoassay of carbohydrate antigen 19-9. Analyst 2008, 133:184-190.
111. Zhao Y., Zhao X., Pei X., Hu J., Zhao W., Chen B., et al. Multiplex detection of tumor markers with photonic suspension array. Anal Chim Acta 2009, 633:103-108.
112. Jokerst J.V., Raamanathan A., Christodoulides N., Floriano P.N., Pollard A.A., Simmons G.W., et al. Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels. Biosens Bioelectron 2009, 24:3622-3629.
113. Wang J., Yau S.T. Field-effect amperometric immuno-detection of protein biomarker. Biosens Bioelectron 2011, 29:210-214.
114. Ou C., Yuan R., Chai Y., Tang M., Chai R., He X. A novel amperometric immunosensor based on layer-by-layer assembly of gold nanoparticles-multi-walled carbon nanotubes-thionine multilayer films on polyelectrolyte surface. Anal Chim Acta 2007, 603:205-213.
115. Tang H., Chen J., Nie L., Kuang Y., Yao S. A label-free electrochemical immunoassay for carcinoembryonic antigen (CEA) based on gold nanoparticles (AuNPs) and nonconductive polymer film. Biosens Bioelectron 2007, 22:1061-1067.
116. Lai G., Yan F., Ju H. Dual signal amplification of glucose oxidase-functionalized nanocomposites as a trace label for ultrasensitive simultaneous multiplexed electrochemical detection of tumor markers. Anal Chem 2009, 81:9730-9736.
117. Viswanathan S., Rani C., Vijay Anand A., Ho J.A. Disposable electrochemical immunosensor for carcinoembryonic antigen using ferrocene liposomes and MWCNT screen-printed electrode. Biosens Bioelectron 2009, 24:1984-1989.
118. Ho J.A., Lin Y.C., Wang L.S., Hwang K.C., Chou P.T. Carbon nanoparticle-enhanced immunoelectrochemical detection for protein tumor marker with cadmium sulfide biotracers. Anal Chem 2009, 81:1340-1346.
119. Liu M., Jia C., Huang Y., Lou X., Yao S., Jin Q., et al. Highly sensitive protein detection using enzyme-labeled gold nanoparticle probes. Analyst 2010, 135:327-331.
120. Hu M., He Y., Song S., Yan J., Lu H.T., Weng L.X., et al. DNA-bridged bioconjugation of fluorescent quantum dots for highly sensitive microfluidic protein chips. Chem Commun (Camb) 2010, 46:6126-6128.
121. Jie G.F., Liu P., Zhang S.S. Highly enhanced electrochemiluminescence of novel gold/silica/CdSe-CdS nanostructures for ultrasensitive immunoassay of protein tumor marker. Chem Commun (Camb) 2010, 46:1323-1325.
122. Xiang Y., Zhang Y., Chang Y., Chai Y., Wang J., Yuan R. Reverse-micelle synthesis of electrochemically encoded quantum dot barcodes: application to electronic coding of a cancer marker. Anal Chem 2010, 82:1138-1141.
123. Hu M., Yan J., He Y., Lu H., Weng L., Song S., et al. Ultrasensitive, multiplexed detection of cancer biomarkers directly in serum by using a quantum dot-based microfluidic protein chip. ACS Nano 2010, 4:488-494.
124. Gao X., Zhang Y., Chen H., Chen Z., Lin X. Amperometric immunosensor for carcinoembryonic antigen detection with carbon nanotube-based film decorated with gold nanoclusters. Anal Biochem 2011, 414:70-76.
125. Gao X., Zhang Y., Wu Q., Chen H., Chen Z., Lin X. One step electrochemically deposited nanocomposite film of chitosan-carbon nanotubes-gold nanoparticles for carcinoembryonic antigen immunosensor application. Talanta 2011, 85:1980-1985.
126. Lai G., Wu J., Leng C., Ju H., Yan F. Disposable immunosensor array for ultrasensitive detection of tumor markers using glucose oxidase-functionalized silica nanosphere tags. Biosens Bioelectron 2011, 26(9):3782-3787.
127. Li Q., Tang D., Tang J., Su B., Huang J., Chen G. Carbon nanotube-based symbiotic coaxial nanocables with nanosilica and nanogold particles as labels for electrochemical immunoassay of carcinoembryonic antigen in biological fluids. Talanta 2011, 84:538-546.
128. Tabakman S.M., Chen Z., Casalongue H.S., Wang H., Dai H. A new approach to solution-phase gold seeding for SERS substrates. Small 2011, 7:499-505.
129. Song Z., Yuan R., Chai Y., Jiang W., Su H., Che X., et al. Simultaneous immobilization of glucose oxidase on the surface and cavity of hollow gold nanospheres as labels for highly sensitive electrochemical immunoassay of tumor marker. Biosens Bioelectron 2011, 26:2776-2780.
130. Huang K.J., Niu D.J., Xie W.Z., Wang W. A disposable electrochemical immunosensor for carcinoembryonic antigen based on nano-Au/multi-walled carbon nanotubes-chitosans nanocomposite film modified glassy carbon electrode. Anal Chim Acta 2010, 659:102-108.
131. Kong F.Y., Xu M.T., Xu J.J., Chen H.Y. A novel lable-free electrochemical immunosensor for carcinoembryonic antigen based on gold nanoparticles-thionine-reduced graphene oxide nanocomposite film modified glassy carbon electrode. Talanta 2011, 85:2620-2625.
132. Qian J., Dai H., Pan X., Liu S. Simultaneous detection of dual proteins using quantum dots coated silica nanoparticles as labels. Biosens Bioelectron 2011, 28:314-319.
133. Bothara M., Venkatraman V., Reddy R.K., Barrett T., Carruthers J., Prasad S. Nanomonitors: electrical immunoassays for protein biomarker profiling. Nanomedicine (Lond) 2008, 3:423-436.
134. Seux M., Iovanna J., Dagorn J.C., Dusetti N.J. MicroRNAs in pancreatic ductal adenocarcinoma: new diagnostic and therapeutic clues. Pancreatology 2009, 9:66-72.
135. Fang S., Lee H.J., Wark A.W., Corn R.M. Attomole microarray detection of microRNAs by nanoparticle-amplified SPR imaging measurements of surface polyadenylation reactions. J Am Chem Soc 2006, 128:14044-14046.
136. Yang W.J., Li X.B., Li Y.Y., Zhao L.F., He W.L., Gao Y.Q., et al. Quantification of microRNA by gold nanoparticle probes. Anal Biochem 2008, 376:183-188.
137. Liang R.Q., Li W., Li Y., Tan C.Y., Li J.X., Jin Y.X., et al. An oligonucleotide microarray for microRNA expression analysis based on labeling RNA with quantum dot and nanogold probe. Nucleic Acids Res 2005, 33:e17.
138. Gao Z., Yang Z. Detection of microRNAs using electrocatalytic nanoparticle tags. Anal Chem 2006, 78:1470-1477.
139. Hwang do W., Song I.C., Lee D.S., Kim S. Smart magnetic fluorescent nanoparticle imaging probes to monitor microRNAs. Small 2010, 6:81-88.
140. Peng Y., Yi G., Gao Z. A highly sensitive microRNA biosensor based on ruthenium oxide nanoparticle-initiated polymerization of aniline. Chem Commun (Camb) 2010, 46:9131-9133.
141. Peng Y., Gao Z. Amplified detection of microRNA based on ruthenium oxide nanoparticle-initiated deposition of an insulating film. Anal Chem 2011, 83:820-827.
142. Kumagai M., Sarma T.K., Cabral H., Kaida S., Sekino M., Herlambang N., et al. Enhanced in vivo magnetic resonance imaging of tumors by PEGylated iron-oxide-gold core-shell nanoparticles with prolonged blood circulation properties. Macromol Rapid Commun 2010, 31:1521-1528.
143. Jain K.K. Role of nanobiotechnology in the development of personalized medicine. Nanomedicine (Lond) 2009, 4:249-252.
144. Vizirianakis I.S. Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. Nanomedicine 2011, 7:11-17.
145. Bayraktar S., Rocha-Lima C.M. Advanced or metastatic pancreatic cancer: molecular targeted therapies. Mt Sinai J Med 2010, 77:606-619.
146. Christophi C., Winkworth A., Muralihdaran V., Evans P. The treatment of malignancy by hyperthermia. Surg Oncol 1998, 7:83-90.
147. Oleson J.R. Eugene robertson special lecture. Hyperthermia from the clinic to the laboratory: a hypothesis. Int J Hyperthermia 1995, 11:315-322.
148. Hayashi S., Kano E., Tsuji K., Furukawa-Furuya M., Yoshikawa S., Hatashita M., et al. Modification of thermosensitivity and chemosensitivity induced by combined treatments with hyperthermia and adriamycin. Int J Mol Med 2001, 8:417-422.
149. Hermisson M., Weller M. Hyperthermia enhanced chemosensitivity of human malignant glioma cells. Anticancer Res 2000, 20:1819-1823.
150. Hadjicostas P., Malakounides N., Varianos C., Kitiris E., Lerni F., Symeonides P. Radiofrequency ablation in pancreatic cancer. HPB (Oxford) 2006, 8:61-64.
151. Bown S.G., Rogowska A.Z., Whitelaw D.E., Lees W.R., Lovat L.B., Ripley P., et al. Photodynamic therapy for cancer of the pancreas. Gut 2002, 50:549-557.
152. Curley S.A., Cherukuri P., Briggs K., Patra C.R., Upton M., Dolson E., et al. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. J Exp Ther Oncol 2008, 7:313-326.
153. Gannon C.J., Cherukuri P., Yakobson B.I., Cognet L., Kanzius J.S., Kittrell C., et al. Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer 2007, 110:2654-2665.
154. Kam N.W., O'Connell M., Wisdom J.A., Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci USA 2005, 102:11600-11605.
155. Chakravarty P., Marches R., Zimmerman N.S., Swafford A.D., Bajaj P., Musselman I.H., et al. Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes. Proc Natl Acad Sci USA 2008, 105:8697-8702.
156. Burke A., Ding X., Singh R., Kraft R.A., Levi-Polyachenko N., Rylander M.N., et al. Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci USA 2009, 106:12897-12902.
157. Xu J., Jin C., Hao S., Luo G., Fu D. Pancreatic cancer: gene therapy approaches and gene delivery systems. Expert Opin Biol Ther 2010, 10:73-88.
158. Galanis E., Carlson S.K., Foster N.R., Lowe V., Quevedo F., McWilliams R.R., et al. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Mol Ther 2008, 16:979-984.
159. Chawla S.P., Chua V.S., Fernandez L., Quon D., Blackwelder W.C., Gordon E.M., et al. Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. Mol Ther 2010, 18:435-441.
160. Pirollo K.F., Rait A., Zhou Q., Hwang S.H., Dagata J.A., Zon G., et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007, 67:2938-2943.
161. Zhang C., Pei J., Kumar D., Sakabe I., Boudreau H.E., Gokhale P.C., et al. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles. Methods Mol Biol 2007, 361:163-185.
162. Pittella F., Zhang M., Lee Y., Kim H.J., Tockary T., Osada K., et al. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. Biomaterials 2011, 32:3106-3114.
163. Ripka S., Neesse A., Riedel J., Bug E., Aigner A., Poulsom R., et al. CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut 2010, 59:1101-1110.
164. Luo G., Jin C., Long J., Fu D., Yang F., Xu J., et al. RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles. Cancer Biol Ther 2009, 8:594-598.
165. Showalter S.L., Huang Y.H., Witkiewicz A., Costantino C.L., Yeo C.J., Green J.J., et al. Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. Cancer Biol Ther 2008, 7:1584-1590.
166. Misra R., Acharya S., Sahoo S.K. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today 2010, 15:842-850.
167. Tan W.B., Jiang S., Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007, 28:1565-1571.
168. Posadas I., Guerra F.J., Cena V. Nonviral vectors for the delivery of small interfering RNAs to the CNS. Nanomedicine (Lond) 2010, 5:1219-1236.
169. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378(9791):607-620.
170. Xie J., Lee S., Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 2010, 62:1064-1079.
171. Collisson E.A., Sadanandam A., Olson P., Gibb W.J., Truitt M., Gu S., et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011, 17:500-503.
172. Ko A.H., Tempero M.A. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology 2009, 136:43-45.
173. Sumer B., Gao J. Theranostic nanomedicine for cancer. Nanomedicine (Lond) 2008, 3:137-140.
174. Sakamoto J.H., van de Ven A.L., Godin B., Blanco E., Serda R.E., Grattoni A., et al. Enabling individualized therapy through nanotechnology. Pharmacol Res 2010, 62:57-89.
175. Lewinski N., Colvin V., Drezek R. Cytotoxicity of nanoparticles. Small 2008, 4:26-49.
176. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect 2006, 114:165-172.
177. Kunzmann A., Andersson B., Thurnherr T., Krug H., Scheynius A., Fadeel B. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta 2011, 1810:361-373.
178. Beg S., Rizwan M., Sheikh A.M., Hasnain M.S., Anwer K., Kohli K. Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol 2011, 63:141-163.
179. Fadeel B., Garcia-Bennett A.E. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev 2010, 62:362-374.
180. Hussain S., Vanoirbeek J.A., Hoet P.H. Interactions of nanomaterials with the immune system. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012, 4(2):169-183.
181. Boisselier E., Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 2009, 38:1759-1782.
182. Kostarelos K., Bianco A., Prato M. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat Nanotechnol 2009, 4:627-633.
183. Kim J.E., Shin J.Y., Cho M.H. Magnetic nanoparticles: an update of application for drug delivery and possible toxic effects. Arch Toxicol 2011, 10.1007/s00204-011-0773-3.
184. Firme C.P., Bandaru P.R. Toxicity issues in the application of carbon nanotubes to biological systems. Nanomedicine 2010, 6:245-256.